At a glance
- Originator Takeda
- Class Osteoporosis therapies
- Mechanism of Action Cathepsin L inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 07 Sep 1998 No-Development-Reported for Postmenopausal osteoporosis in Japan (PO)
- 24 Oct 1996 New profile
- 24 Oct 1996 Preclinical development for Postmenopausal osteoporosis in Japan (PO)